Zymeworks (NASDAQ:ZYME) Price Target Raised to $44.00

Zymeworks (NASDAQ:ZYME) had its target price raised by stock analysts at Citigroup from $39.00 to $44.00 in a report released on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup‘s price objective would indicate a potential upside of 50.63% from the company’s previous close.

ZYME has been the topic of a number of other research reports. Stifel Nicolaus set a $46.00 price target on shares of Zymeworks in a report on Friday, August 7th. Wells Fargo & Company upped their price objective on shares of Zymeworks from $37.00 to $40.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. HC Wainwright upped their price objective on shares of Zymeworks from $55.00 to $56.00 and gave the stock a “buy” rating in a report on Tuesday. JPMorgan Chase & Co. increased their target price on shares of Zymeworks from $31.00 to $33.00 and gave the stock an “overweight” rating in a research report on Thursday, September 3rd. Finally, Deutsche Bank Aktiengesellschaft set a $32.00 target price on Zymeworks in a report on Wednesday, August 26th. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Zymeworks has a consensus rating of “Moderate Buy” and a consensus price target of $42.67.

Zymeworks Price Performance

NASDAQ:ZYME traded down $2.25 during mid-day trading on Wednesday, reaching $29.21. The stock had a trading volume of 338,037 shares, compared to its average volume of 781,592. The business’s 50 day moving average is $27.50 and its 200 day moving average is $25.42. Zymeworks has a fifty-two week low of $18.20 and a fifty-two week high of $31.97. The stock has a market cap of $2.06 billion, a P/E ratio of 56.44 and a beta of 1.32.

Zymeworks (NASDAQ:ZYME) last posted its earnings results on Monday, November 9th. The company reported $2.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.27 by $0.01. The firm had revenue of $512.92 million during the quarter, compared to analysts’ expectations of $227.40 million. Zymeworks had a net margin of 16.10% and a return on equity of 25.07%. The company’s revenue was up 828.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.26) earnings per share. Equities analysts expect that Zymeworks will post 1.32 EPS for the current year.

Insider Activity

In related news, EVP Adam Schayowitz sold 13,832 shares of the firm’s stock in a transaction on Friday, October 9th. The shares were sold at an average price of $25.85, for a total value of $357,557.20. Following the transaction, the executive vice president directly owned 23,205 shares in the company, valued at approximately $599,849.25. This trade represents a 37.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 37.73% of the company’s stock.

Institutional Investors Weigh In On Zymeworks

Hedge funds have recently bought and sold shares of the company. Rubric Capital Management LP grew its position in shares of Zymeworks by 21.7% in the first quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company’s stock valued at $175,280,000 after purchasing an additional 1,250,000 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Zymeworks during the 2nd quarter worth about $111,122,000. Perceptive Advisors LLC lifted its position in shares of Zymeworks by 7.6% during the 1st quarter. Perceptive Advisors LLC now owns 3,510,078 shares of the company’s stock worth $87,892,000 after purchasing an additional 248,228 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Zymeworks by 20.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,508,069 shares of the company’s stock worth $39,949,000 after purchasing an additional 256,042 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its stake in Zymeworks by 6.3% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 743,898 shares of the company’s stock valued at $18,627,000 after purchasing an additional 43,896 shares during the period. 92.89% of the stock is currently owned by institutional investors.

Key Headlines Impacting Zymeworks

Here are a few of the latest headlines about ZYME:

• Positive Sentiment: Higher 2026 earnings guidance: Zymeworks raised its earnings outlook for the year, supporting the investment case. Zymeworks raises 2026 earnings guidance
• Positive Sentiment: Profitability and revenue beat: The company swung to a profit, with reported third-quarter revenue of $256.5 million versus a FactSet estimate of $227.4 million. A $250 million Jazz milestone was a key contributor, though its size suggests the quarter’s results may not reflect recurring revenue. Zymeworks swings to a profit on a Jazz milestone
• Positive Sentiment: Analyst targets increased: TD Cowen raised its target to $39, Truist Financial to $36, and HC Wainwright to $56; all retained Buy ratings. These revisions indicate greater analyst optimism. TD Cowen rating

Zymeworks Company Profile

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.